CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 17 enrolled
Drug / intervention
Topical Tranexamic Acid 5% with bacitracin +1 moredrug
Likely dose
Topical Tranexamic Acid 5% with bacitracin 5 %from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02106962
NCT02106962Phase 4Completed
CompareCT.gov

The Use of Topical Tranexamic Acid and Bacitracin in Dialysis Patients

California Institute of Renal Research·interventional·Posted Apr 8, 2014·Updated Sep 25, 2017

In Brief

A Phase 4 clinical trial evaluating Topical Tranexamic Acid 5% with bacitracin and Topical Tranexamic Acid 25% with bacitracin for Arteriovenous Fistula. Completed, enrolled 17 participants across 3 sites.

Detailed Summary

This study will investigate how the use of Tranexamic acid and Bacitracin applied to the bleeding site after the hemodialysis fistula needle is removed will affect Time to Clot and Infection Rate

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsArteriovenous Fistula
CountriesUnited States
CollaboratorsImprimis Pharmaceuticals, Inc.

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 8, 2014
Enrollment StartApr 1, 2014
Primary CompletionAug 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 12.2 years ago

Interventions

Topical Tranexamic Acid 5% with bacitracindrug

Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.

Topical Tranexamic Acid 25% with bacitracinother

Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.